Eli Lilly and Company (NYSE:LLY) Shares Sold by Cary Street Partners Financial LLC

Key Points

• Cary Street Partners Financial LLC has reduced its stake in Eli Lilly and Company by 1.5% during the 1st quarter, now holding 25,946 shares worth approximately $21.43 million.
• Eli Lilly has announced a quarterly dividend of $1.50 per share, with an annualized yield of 0.8%, payable on September 10th to shareholders of record as of August 15th.
• Wall Street analysts have mixed views on Eli Lilly, with a consensus rating of "Moderate Buy" and a target price of $1,012.56, stemming from varying ratings and price targets issued by firms like Morgan Stanley and HSBC.

Cary Street Partners Financial LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,946 shares of the company's stock after selling 393 shares during the quarter. Eli Lilly and Company makes up about 0.7% of Cary Street Partners Financial LLC's portfolio, making the stock its 29th biggest holding. Cary Street Partners Financial LLC's holdings in Eli Lilly and Company were worth $21,429,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Knightsbridge Asset Management LLC raised its stake in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after acquiring an additional 15 shares during the period. LS Investment Advisors LLC raised its stake in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares during the period. Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $207,000. CSM Advisors LLC raised its stake in shares of Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after acquiring an additional 245 shares during the period. Finally, Bfsg LLC raised its stake in shares of Eli Lilly and Company by 1.4% in the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after acquiring an additional 42 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.7%

Shares of NYSE:LLY opened at $767.75 on Tuesday. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm's 50 day moving average price is $776.59 and its 200 day moving average price is $800.81. The stock has a market cap of $727.63 billion, a price-to-earnings ratio of 62.47, a price-to-earnings-growth ratio of 1.08 and a beta of 0.44.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LLY. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Finally, Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.